Halozyme Therapeutics (NASDAQ:HALO) is a biotechnology company specializing in drug delivery technologies and the development of patient-friendly formulations. At the core of its platform is ENHANZE, a proprietary technology based on recombinant human hyaluronidase (rHuPH20) that facilitates the rapid and efficient delivery of therapies by temporarily depolymerizing hyaluronan in the extracellular matrix. This approach enables subcutaneous administration of large-molecule drugs, offering shorter infusion times and greater convenience compared to traditional intravenous treatments.
Founded in 1998 and headquartered in San Diego, California, Halozyme built its reputation by commercializing Hylenex recombinant (hyaluronidase human injection), which is co‐formulated with select products to improve absorption and dispersion. Over the years, the company has entered into strategic collaborations with leading global pharmaceutical and biotechnology firms—including Roche, Pfizer and Janssen—to apply ENHANZE in oncology, immunology and other therapeutic areas. These partnerships extend Halozyme’s reach across North America, Europe and Asia, with clinical studies conducted worldwide.
Halozyme’s business model combines royalty revenues from product sales, milestone payments and research fees from partners, as well as potential revenue from proprietary pipeline candidates. Beyond its enabling technology, the company is advancing its own investigational programs in areas such as immuno-oncology and oncology combination therapies. Its R&D efforts are supported by a diverse team of scientists and clinical experts focused on improving patient outcomes through novel delivery mechanisms.
Under the leadership of President and Chief Executive Officer Helen A. Kim, Ph.D., Halozyme continues to expand its platform and pipeline while fostering new alliances. The company’s management team brings extensive experience in drug development, regulatory affairs and global commercialization, positioning Halozyme to address evolving industry needs and to deliver innovative solutions that enhance the efficacy and accessibility of therapeutics.
